Karyopharm Therapeutics Inc. (KPTI:NASDAQ) closed at $0.546 on October 22, 2026, up 28.68% on the day. The stock trades 95.0% below its 52-week high of $10.99 and 76.2% above its 52-week low of $0.310. Over the past year, it lost 91.2%. Karyopharm Therapeutics Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 22, 2025, KPTI closed higher on 121 days (48%). Its best day was October 22, 2026 (+28.68%) and its worst was July 31, 2026 (-72.61%). The stock moved 10% or more in a single session 24 times. It opened at least 5% above the previous day's high 1 time.
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases....
Find more stocks like KPTI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.